Wearable Device Monitors Vital Signs Continuously

During the week long monitoring session, the device is also capable of recording full interpretive ECG data for download and analysis by a trained healthcare professional. The system provides full configurability of the duration and frequency of monitored data, including the length of each recorded event.

Features of the system include 3-lead ECG full disclosure and cardiac event monitoring; symptomatic and asymptomatic arrhythmia event detection using on-device algorithms; monitoring of heart rate, respiration, and motion; and a rechargeable battery, replaceable in situ, when needed for extended periods of continuous use. The highly miniaturized, reusable, compact and lightweight body-worn wireless sensor is non-irritant, and is easy-to-apply using the long-life patch electrodes.

Transmission of detected arrhythmias and rate limit breaches is over standard Wi-Fi or mobile hotspot to the zensoronline website, with normal ranges and pre and post event data reporting configurable by the clinician. Data can also be downloaded via USB to zensor+ software. The Zensor vital signs monitor is a product of Intelesens (Belfast, United Kingdom), and has been approved by the US Food and Drug Administration (FDA).

“FDA clearance gives Intelesens and customers confidence in Zensor’s quality, robustness, and clinical efficacy,” said Stephen Henderson, commercial manager of Intelesens. “It brings a step closer the promise of preventative, predictive and protective technology, enabling clinicians proactively to help safeguard the quality of the life patients have yet to live.”

Related Links:
Intelesens
Zensoronline